On Friday, Following Stocks were among the “Top 100 Gainers” In U.S. Stock Exchange: Cempra Inc (NASDAQ:CEMP), WhiteWave Foods Co (NYSE:WWAV), Geron Corporation (NASDAQ:GERN), VIVUS, Inc (NASDAQ:VVUS)
Cempra Inc (NASDAQ:CEMP)’s shares picked up 3.26%, and closed at $32.00. The stock has the beta value of 0.73, and its volatility for the week is 8.42%, while for the month it is 5.82%. The company has the market capitalization of $1.39B. The company holds the book value per share of 1.67, whereas cash per share is 2.28. Price to book ratio remained 91.64, while price to sale ratio is 19.16. Analysts mean recommendation for the stock is said to be 1.50 (where 1=Buy, 5=sale).
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates comprise solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community attaind bacterial pneumonia, in addition to for uncomplicated bacterial urethritis; and Taksta (CEM-102), an antibiotic that has accomplished Phase II clinical trials for refractory bone and joint infections. The company also produces novel macrolides for non-antibiotic uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.
WhiteWave Foods Co (NYSE:WWAV), raised 3.22%, and closed at $45.23, hitting new 52-week high of $45.32. The company holds the market capitalization of $7.89B. For the last twelve months, the stock was able to keep return on equity at 13.40%, while return on assets at 4.40%, in response to its return on investment at 7.30%. Its 20-day moving average gained 7.36%, above 50-day moving average of 17.63%, above 200-day moving average of 28.16% from the latest market price of $45.23. The mean recommendation of analysts for this stock is 1.80.(where 1=Buy, 5=Sale).
The WhiteWave Foods Company, a consumer packaged food and beverage company, manufactures, markets, distributes, and sells branded plant-based foods and beverages, salads, fruits and vegetables, coffee creamers and beverages, and dairy products and organic produce in North America and Europe. It operates in three segments: Americas Foods & Beverages, Americas Fresh Foods, and Europe Foods & Beverages. The Americas Foods & Beverages segment offers plant-based foods and beverages, such as soymilk, almond milk, and coconut milk under the Silk and So Delicious brands; dairy products, counting Horizon Organic milk, yogurt, cheese, and other dairy products, in addition to Horizon branded macaroni and cheese, and snack foods; and coffee creamers and ready-to-drink beverages under the International Delight and LAND O LAKES brands. The Americas Fresh Foods segment provides packaged salad greens, fresh and frozen fruits and vegetables, dried fruits, and produce-based snacks under the Earthbound Farm brand.
Geron Corporation (NASDAQ:GERN), enhanced 3.22%, and closed at $3.85. The company has the market capitalization of $607.15M. The beta value of the stock is 2.11. On the other hand the stock’s volatility for the week is 6.39%, and for the month is 8.54%. The stock’s price to book ratio is 4.64, however price to sale ratio is 505.92. Analyst’s mean recommendation regarding this stock is 2.50. (where 1=Buy, 5=Sale).
Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. The Company operates in one segment, the discovery and development of therapeutic products for oncology.
VIVUS, Inc (NASDAQ:VVUS), rose 3.21%, and closed at $2.57. The stock volatility for the week is 5.47%, while for the month remained 6.56%. The company holds consensus target price of $4.00.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.80diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 53.80% and Annual EPS growth for the past 5 years is considered as -1.80%.
The mean recommendation of analysts for this stock is 3.30. (where 1=Buy, 5=Sale).
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and raised physical activity for chronic weight administration in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
